open access

Vol 67, No 1 (2017)
Review paper
Published online: 2017-08-24
Get Citation

Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage

Beata Jagielska, Konrad Tałasiewicz, Aleksandra Czachowska, Katarzyna Gepner, Elżbieta Mądro, Małgorzata Symonides, Paweł Wiechno, Maciej Krzakowski
DOI: 10.5603/NJO.2017.0005
·
Nowotwory. Journal of Oncology 2017;67(1):34-40.

open access

Vol 67, No 1 (2017)
Review article
Published online: 2017-08-24

Abstract

Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.

Abstract

Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.

Get Citation

Keywords

cardiotoxicity, molecular target therapy, arterial hypertension, cardiac failure, arrhythmias, drug side-effects

About this article
Title

Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage

Journal

Nowotwory. Journal of Oncology

Issue

Vol 67, No 1 (2017)

Article type

Review paper

Pages

34-40

Published online

2017-08-24

DOI

10.5603/NJO.2017.0005

Bibliographic record

Nowotwory. Journal of Oncology 2017;67(1):34-40.

Keywords

cardiotoxicity
molecular target therapy
arterial hypertension
cardiac failure
arrhythmias
drug side-effects

Authors

Beata Jagielska
Konrad Tałasiewicz
Aleksandra Czachowska
Katarzyna Gepner
Elżbieta Mądro
Małgorzata Symonides
Paweł Wiechno
Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl